2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphoma
2022
S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T‐CELL LYMPHOMA AND 51 CUTANEOUS T‐CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.
Michot J, Mehta A, Samaniego F, Bachy E, Zinzani P, Prica A, Colins G, Ribrag V, Wagner‐Johnston N, El‐Sharkawi D, O'Connor O, Wilcox R, Wang L, Wilson L, Sims M, Taylor J, Keer H, Foss F. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T‐CELL LYMPHOMA AND 51 CUTANEOUS T‐CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE. HemaSphere 2022, 6: 118-119. DOI: 10.1097/01.hs9.0000843760.14993.43.Peer-Reviewed Original Research
2017
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Transplantation And Cellular Therapy 2017, 23: 1826-1838. PMID: 28797780, DOI: 10.1016/j.bbmt.2017.07.027.Peer-Reviewed Original ResearchConceptsAngioimmunoblastic T-cell lymphomaNK/T cellsT-cell lymphomaFront-line consolidationClinical practice recommendationsHematopoietic cell transplantationALCL-ALKAuto-HCTT cellsAllo-HCTHepatosplenic lymphomaCell lymphomaHistological subtypesMature T cellsRefractory diseaseMarrow transplantationNatural killerPTCL-NOSCell transplantationAnaplastic large cell lymphoma-anaplastic lymphoma kinaseMycosis fungoides/Sezary syndromeNK/T-cell lymphomaAutologous hematopoietic cell transplantationPeripheral T-cell lymphomaAdult T-cell leukemia/lymphomaMycosis Fungoides and Sezary Syndrome
Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematology/Oncology Clinics Of North America 2017, 31: 297-315. PMID: 28340880, DOI: 10.1016/j.hoc.2016.11.008.Peer-Reviewed Original ResearchConceptsSkin-directed therapiesSezary syndromeLymph nodesMycosis fungoidesAllogeneic stem cell transplantationSystemic immunomodulatory agentsVisceral organ involvementSingle-agent chemotherapyStem cell transplantationPatch/plaqueHelper T cellsExtent of skinDiffuse erythrodermaBlood involvementOrgan involvementRefractory diseaseVisceral involvementResistant diseaseRare lymphomaCell transplantationImmunomodulatory agentsPlaque diseaseCurative strategiesT cellsDisease
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapy
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDisease